Literature DB >> 33024996

Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.

Javier Raboso-Gallego1,2, Ana Casado-García1,2, Xiaoyu Jiang3, Marta Isidro-Hernández1,2, Andrew J Gentles4,5, Shuchun Zhao6, Yaso Natkunam6, Oscar Blanco2,7, Verónica Domínguez8, Belén Pintado8, Diego Alonso-López9, Javier De Las Rivas2,10, Carolina Vicente-Dueñas2, Izidore S Lossos3,11, Isidro Sanchez-Garcia1,2.   

Abstract

Diffuse large B-cell lymphomas (DLBCLs) are clinically and genetically heterogeneous tumors. Deregulation of diverse biological processes specific to B cells, such as B-cell receptor (BCR) signaling and motility regulation, contribute to lymphomagenesis. Human germinal center associated lymphoma (HGAL) is a B-cell-specific adaptor protein controlling BCR signaling and B lymphocyte motility. In normal B cells, it is expressed in germinal center (GC) B lymphocytes and promptly downregulated upon further differentiation. The majority of DLBCL tumors, primarily GC B-cell types, but also activated types, express HGAL. To investigate the consequences of constitutive expression of HGAL in vivo, we generated mice that conditionally express human HGAL at different stages of hematopoietic development using 3 restricted Cre-mediated approaches to initiate expression of HGAL in hematopoietic stem cells, pro-B cells, or GC B cells. Following immune stimulation, we observed larger GCs in mice in which HGAL expression was initiated in GC B cells. All 3 mouse strains developed DLBCL at a frequency of 12% to 30% starting at age 13 months, leading to shorter survival. Immunohistochemical studies showed that all analyzed tumors were of the GC B-cell type. Exon sequencing revealed mutations reported in human DLBCL. Our data demonstrate that constitutive enforced expression of HGAL leads to DLBCL development.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33024996      PMCID: PMC8020264          DOI: 10.1182/blood.2020004996

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Summaries of Affymetrix GeneChip probe level data.

Authors:  Rafael A Irizarry; Benjamin M Bolstad; Francois Collin; Leslie M Cope; Bridget Hobbs; Terence P Speed
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

3.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

Review 4.  Genetic alterations and their clinical implications in DLBCL.

Authors:  Yi Miao; L Jeffrey Medeiros; Yong Li; Jianyong Li; Ken H Young
Journal:  Nat Rev Clin Oncol       Date:  2019-10       Impact factor: 66.675

5.  Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).

Authors:  Joaquim Carreras; Yara Y Kikuti; Sílvia Beà; Masashi Miyaoka; Shinichiro Hiraiwa; Haruka Ikoma; Ryoko Nagao; Sakura Tomita; David Martin-Garcia; Itziar Salaverria; Ai Sato; Akifumi Ichiki; Giovanna Roncador; Juan F Garcia; Kiyoshi Ando; Elias Campo; Naoya Nakamura
Journal:  Histopathology       Date:  2017-01-09       Impact factor: 5.087

6.  BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.

Authors:  Jonathan Mandelbaum; Govind Bhagat; Hongyan Tang; Tongwei Mo; Manisha Brahmachary; Qiong Shen; Amy Chadburn; Klaus Rajewsky; Alexander Tarakhovsky; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

7.  Regulation of AID expression in the immune response.

Authors:  Elizabeth E Crouch; Zhiyu Li; Makiko Takizawa; Stefan Fichtner-Feigl; Polyxeni Gourzi; Carolina Montaño; Lionel Feigenbaum; Patrick Wilson; Siegfried Janz; F Nina Papavasiliou; Rafael Casellas
Journal:  J Exp Med       Date:  2007-04-23       Impact factor: 14.307

8.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.

Authors:  Georg Lenz; George W Wright; N C Tolga Emre; Holger Kohlhammer; Sandeep S Dave; R Eric Davis; Shannon Carty; Lloyd T Lam; A L Shaffer; Wenming Xiao; John Powell; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Lisa M Rimsza; Richard I Fisher; Dennis D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-02       Impact factor: 11.205

9.  Isolation and characterization of a novel B cell activation gene.

Authors:  J X Hong; G L Wilson; C H Fox; J H Kehrl
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

10.  Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.

Authors:  Laura Pasqualucci; Mara Compagno; Jane Houldsworth; Stefano Monti; Adina Grunn; Subhadra V Nandula; Jon C Aster; Vundavally V Murty; Margaret A Shipp; Riccardo Dalla-Favera
Journal:  J Exp Med       Date:  2006-02-20       Impact factor: 14.307

View more
  1 in total

1.  HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteins.

Authors:  Xiaoyu Jiang; XiaoQing Lu; Andrew J Gentles; Dekuang Zhao; Seth A Wander; Yu Zhang; Yasodha Natkunam; Joyce Slingerland; Isildinha M Reis; Brian Rabinovich; Midhat H Abdulreda; Vincent T Moy; Izidore S Lossos
Journal:  Blood Adv       Date:  2021-12-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.